Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from MSD

New Zealand announces major overhaul of seasonal worker scheme; changes from 2027

New Zealand's Recognised Seasonal Employer scheme will see reforms starting in 2027. These changes aim to simplify recruitment and improve worker protections for overseas staff. Employers will experience streamlined accreditation and agreement processes under the new framework. Workers will benefit from strengthened support and clearer cost recovery agreements. The government…

The Economic Times

Merck-Backed Lab Gets $8.5 Million to Fast-Track a Vaccine for a Rapidly Spreading Ebola Outbreak

Hilleman Laboratories, a Singapore-based joint venture of Merck & Co. Inc. (NYSE:MRK) MSD division and Wellcome, said Thursday it will develop and manufacture clinical trial doses of an investigational Bundibugyo Ebola vaccine with up to $8.5 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI).

Benzinga

New NHS cancer jab means treatment could take minutes rather than hours

Until now, patients have had to spend hours on a drip to get the drug pembrolizumab (Keytruda) to treat their cancer.

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Tens of thousands could benefit from one-minute cancer jab on the NHS

Until now, patients have had to spend hours on a drip to get the drug pembrolizumab (Keytruda) to treat their cancer.

Evening Standard

Tens of thousands could benefit from one-minute cancer jab rolled out on the NHS

Currently, hospital pharmacy teams need to carefully prepare the drug in intravenous bags under sterile conditions, which can be time-consuming for NHS staff

The Independent UK

‘Patients will suffer’: tales from the frontline of the UK pharma crisis

The pricing standoff between government and industry has stalled research and put thousands of jobs at risk

The Guardian - UK

NHS could pay 25% more for medicines under plan to end row with drugmakers and Trump

UK ministers preparing to raise payments to end standoff with pharma industry, cited as reason for firms axing British investments

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

UK set on resolving standoff with big pharma, science minister says

Patrick Vallance says relations must improve and NHS has to reverse decline in drugs investment

The Guardian - UK

UK ‘difficult’ operating environment says Merck boss after £1bn London site axed

Last week, Merck’s business in the UK and Europe, MSD, said it will move its life sciences operation to the US, impacting around 125 British jobs.

Evening Standard

Big pharma firms have paused nearly £2bn in UK investments this year

Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears

The Guardian - UK

Merck’s move to axe £1bn UK expansion was ‘commercial decision’, says minister

The Conservatives said Merck’s decision should send alarm bells ringing across Government.

Evening Standard

Pharma giant ditches £1bn London research hub and says UK ‘is not internationally competitive’

Merck, known as MSD in Europe, criticised the UK’s business environment despite the government saying it has become ‘the most attractive place to invest in the world’

The Independent UK

US drugmaker Merck scraps £1bn London research centre and cuts 125 science jobs

New blow to UK’s key life science sector as industry body says country is losing ground on investment and research

The Guardian - UK

‘Touch and go’: Reading stuck in brinkmanship battle over sale as deadline looms

Reading are trapped in a three-way battle of brinkmanship involving owner Dai Yongge and two potential buyers, leaving staff at the club fearing they will be forced into administration next month.

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Proposed sale of Reading to Robert Platek faces conflict of interest concerns

A company for which Robert Platek works has lent money to other EFL clubs, leading one executive at another club to remark: ‘At best it doesn’t look good’

The Conversation

One of science’s greatest achievements: how the rapid development of COVID vaccines prepares us for future pandemics

Since COVID was first reported in December 2019, there have been more than 775 million recorded infections and more than 7 million deaths from the disease. This makes COVID the seventh-deadliest pandemic in recorded history.

The Conversation

Your gas stove might be making your asthma worse. Here’s what you can do about it

We may think of air pollution as an outdoor problem, made up of car exhaust and smog. But if the air inside our homes is polluted, this can also affect our health.

The Conversation

New COVID vaccines may be coming to Australia. Here’s what to know about the JN.1 shots

COVID vaccines have unquestionably made a huge difference during this pandemic. For example, it’s estimated COVID shots have saved more than 1.4 million lives in the World Health Organization’s (WHO) European region alone since their introduction in December 2020.

Get all your
news in one place.

100's of premium titles.
One news app.

USA Today Sports Media Group

Boston Celtics retain multiple companies to assist in franchise’s sale

The Boston Celtics have retained the world-leading companies to assist in the sale of the franchise.

StockNews.com

3 Healthcare Stocks Benefiting From an Aging Population

The healthcare industry is set for growth due to the growing demand for quality healthcare services and the aging population. Hence, quality healthcare stocks, such as Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck & Co. (MRK), might be worth looking into. Read more….

StockNews.com

3 Pharmaceutical Stocks With Strong Pipelines

The pharmaceutical industry is flourishing due to increasing medical demands and rising healthcare spending worldwide. Hence, pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Merck & Co. (MRK), with strong pipelines, might be worth buying. Read more….

The Times of India

IPL: Leg-muscle tear forcing MS Dhoni to bat down the order

Movements are severely restricted but team's injury issues not allowing legend to take a break

The Times of India

IPL 2024: How MS Dhoni is using the 'Impact Player' rule

NEW DELHI: The 'Impact Player' rule, according to Michael Hussey, the batting coach for the Chennai Super Kings, has extended their batting order, enabling former captain Mahendra Singh Dhoni to bat as late as number eight in this IPL.

The Times of India

6th trophy loading!: MS Dhoni's colossal sixes during CSK net session are 'pure goosebumps'. Watch

NEW DELHI: Gearing up for the upcoming season of the Indian Premier League, Chennai Super Kings' MS Dhoni was seen launching the balls into orbit during the team's training session at the Chepauk.

The Times of India

MS Dhoni's final IPL season? AB de Villiers gives a major update on the legend

NEW DELHI: As MS Dhoni gears up for another IPL season with the Chennai Super Kings (CSK), speculation looms over whether this might be his final campaign in the league. Having led CSK to their fifth title triumph in the previous season, Dhoni's leadership and experience remain invaluable assets for…

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.